The management of pancreatic tumor in hereditary breast and ovarian cancer syndrome
-
- Abe Kodai
- Department of Surgery, Keio University School of Medicine
-
- Kitago Minoru
- Department of Surgery, Keio University School of Medicine HBOC Center, Keio University School of Medicine
-
- Kobayashi Yusuke
- HBOC Center, Keio University School of Medicine Department of Obstetrics and Gynecology, Keio University School of Medicine Center for Medical Genetics, Keio University School of Medicine
-
- Masuda Kenta
- HBOC Center, Keio University School of Medicine Department of Obstetrics and Gynecology, Keio University School of Medicine Center for Medical Genetics, Keio University School of Medicine
-
- Seki Tomoko
- Department of Surgery, Keio University School of Medicine HBOC Center, Keio University School of Medicine
-
- Kosaka Takeo
- HBOC Center, Keio University School of Medicine Department of Urology, Keio University School of Medicine
-
- Ono Ikumi
- HBOC Center, Keio University School of Medicine Nursing Department, Keio University School of Medicine
-
- Misu Kumiko
- HBOC Center, Keio University School of Medicine Nursing Department, Keio University School of Medicine
-
- Nakamura Kohei
- HBOC Center, Keio University School of Medicine Oncology Center, Keio University School of Medicine
-
- Uchida Tomoka
- HBOC Center, Keio University School of Medicine Department of Obstetrics and Gynecology, Keio University School of Medicine
-
- Funakoshi Ken
- HBOC Center, Keio University School of Medicine Department of Dermatology, Keio University School of Medicine
-
- Takeuchi Mari
- HBOC Center, Keio University School of Medicine Department of Psychiatry and Neuroscience, Keio University School of Medicine
-
- Kosaki Kenjiro
- HBOC Center, Keio University School of Medicine Center for Medical Genetics, Keio University School of Medicine
-
- Aoki Daisuke
- HBOC Center, Keio University School of Medicine Department of Obstetrics and Gynecology, Keio University School of Medicine
-
- Kitagawa Yuko
- Department of Surgery, Keio University School of Medicine
Bibliographic Information
- Other Title
-
- HBOC診療における膵腫瘍のマネジメント
Abstract
<p> It is known that 1-3% of BRCA1 pathogenic variant carriers and 2-7% of BRCA2 pathogenic variant carriers develop pancreatic cancer in their lifetime. Recruitment and surveillance of hereditary or familial pancreatic cancer families as high-risk individuals for pancreatic cancer using magnetic resonance cholangiopancreatography (MRCP) and/or endoscopic ultrasonography (EUS), showed to improve the early detection rate and overall survival rate of pancreatic cancer. Therefore, the Hereditary Breast and Ovarian Cancer syndrome (HBOC) Clinical Guideline 2021 recommends pancreatic surveillance for patients with a strong family history of pancreatic cancer or with pathogenic variants of a total of 10 genes including BRCA1/2. In April 2021, the HBOC Center was established by seven departments of Obstetrics and Gynecology, Gastroenterological Surgery (Breast, Hepatobiliary and Pancreas), Urology, Center for Medical Genetics, and Oncology Center, and since October 2021, the department of dermatology, psychiatry and neuroscience have also joined the center, which now operates as nine departments. Pancreatic surveillance has been performed by MRCP or EUS once or twice a year, and we focus on intraductal papillary mucinous neoplasm (IPMN), a precancerous lesion of pancreatic cancer detected during the surveillance, in order not only to explore the risk and interaction of environmental and genetic factors, but also to work on early detection and prevention before IPMN becomes malignant. Furthermore, in January 2021, the germline BRCA1/2 genetic testing for pancreatic cancer as well as breast and ovarian cancer will be covered by insurance as a companion diagnosis to poly ADP-ribose polymerase (PARP) inhibitors, and the test is becoming widely used in our hospital for pancreatic cancer patients, but the indication is still limited only to metastatic pancreatic cancer and insurance has not been covered for HBOC diagnosis or pancreatic cancer surveillance. We believe that it is essential to promote BRCA1/2 genetic testing, as well as genetic counseling, for prevention and early detection of pancreatic cancer in high-risk individuals as well as HBOC syndrome.</p>
Journal
-
- Journal of Hereditary Tumors
-
Journal of Hereditary Tumors 23 (1), 12-16, 2023-06-30
The Japanese Society for Hereditary Tumors
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1390578141473987968
-
- ISSN
- 24356808
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
-
- Abstract License Flag
- Disallowed